Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 208

1.

Starting Out: qualitative perspectives of new graduate nurses and nurse leaders on transition to practice.

Regan S, Wong C, Laschinger HK, Cummings G, Leiter M, MacPhee M, Rhéaume A, Ritchie JA, Wolff AC, Jeffs L, Young-Ritchie C, Grinspun D, Gurnham ME, Foster B, Huckstep S, Ruffolo M, Shamian J, Burkoski V, Wood K, Read E.

J Nurs Manag. 2017 Feb 27. doi: 10.1111/jonm.12456. [Epub ahead of print]

PMID:
28244181
2.

Reply to L. Del Mastro and A. Prat.

Denduluri N, Somerfield MR, Eisen A, Holloway JN, Hurria A, King TA, Lyman GH, Partridge AH, Telli ML, Trudeau ME, Wolff AC.

J Clin Oncol. 2017 Jan 17:JCO2016709758. doi: 10.1200/JCO.2016.70.9758. [Epub ahead of print] No abstract available.

PMID:
28095161
3.

Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.

Kim HS, Umbricht CB, Illei PB, Cimino-Mathews A, Cho S, Chowdhury N, Figueroa-Magalhaes MC, Pesce C, Jeter SC, Mylander C, Rosman M, Tafra L, Turner BM, Hicks DG, Jensen TA, Miller DV, Armstrong DK, Connolly RM, Fetting JH, Miller RS, Park BH, Stearns V, Visvanathan K, Wolff AC, Cope L.

J Clin Oncol. 2016 Dec 20;34(36):4390-4397. Epub 2016 Oct 31.

PMID:
27998227
4.

Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study.

Connolly RM, Li H, Jankowitz RC, Zhang Z, Rudek MA, Jeter SC, Slater SA, Powers P, Wolff AC, Fetting JH, Brufsky A, Piekarz R, Ahuja N, Laird PW, Shen H, Weisenberger DJ, Cope L, Herman JG, Somlo G, Garcia AA, Jones PA, Baylin SB, Davidson NE, Zahnow CA, Stearns V.

Clin Cancer Res. 2016 Dec 15. doi: 10.1158/1078-0432.CCR-16-1729. [Epub ahead of print]

PMID:
27979916
5.

CDK4 and CDK6 Inhibition in Breast Cancer - A New Standard.

Wolff AC.

N Engl J Med. 2016 Nov 17;375(20):1993-1994. No abstract available.

PMID:
27959592
6.

Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.

Visvanathan K, Fackler MS, Zhang Z, Lopez-Bujanda ZA, Jeter SC, Sokoll LJ, Garrett-Mayer E, Cope LM, Umbricht CB, Euhus DM, Forero A, Storniolo AM, Nanda R, Lin NU, Carey LA, Ingle JN, Sukumar S, Wolff AC.

J Clin Oncol. 2017 Mar;35(7):751-758. doi: 10.1200/JCO.2015.66.2080. Epub 2016 Nov 21.

PMID:
27870562
7.

Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer.

Parsons HA, Beaver JA, Cimino-Mathews A, Ali SM, Axilbund J, Chu D, Connolly RM, Cochran RL, Croessmann S, Clark TA, Gocke CD, Jeter SC, Kennedy MR, Lauring J, Lee J, Lipson D, Miller VA, Otto GA, Rosner GL, Ross JS, Slater S, Stephens PJ, VanDenBerg DA, Wolff AC, Young LE, Zabransky DJ, Zhang Z, Zorzi J, Stearns V, Park BH.

Clin Cancer Res. 2017 Jan 15;23(2):379-386. doi: 10.1158/1078-0432.CCR-16-1543. Epub 2016 Aug 3.

PMID:
27489289
8.

Evolving Role of the Estrogen Receptor as a Predictive Biomarker: ESR1 Mutational Status and Endocrine Resistance in Breast Cancer.

Lauring J, Wolff AC.

J Clin Oncol. 2016 Sep 1;34(25):2950-2. doi: 10.1200/JCO.2016.68.4720. Epub 2016 Jul 5. No abstract available.

PMID:
27382095
9.

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR.

N Engl J Med. 2016 Jul 21;375(3):209-19. doi: 10.1056/NEJMoa1604700. Epub 2016 Jun 5.

10.

Still Refining Adjuvant Endocrine Therapy in Premenopausal Women: Not Too Much, Not Too Little.

Wolff AC, Rugo HS.

J Clin Oncol. 2016 Jul 1;34(19):2203-5. doi: 10.1200/JCO.2016.67.0463. Epub 2016 May 16. No abstract available.

PMID:
27185850
11.

Relationship Between Quality of Comorbid Condition Care and Costs for Cancer Survivors.

Frick KD, Snyder CF, Herbert RJ, Blackford AL, Neville BA, Wolff AC, Carducci MA, Earle CC.

J Oncol Pract. 2016 Jun;12(6):e734-45. doi: 10.1200/JOP.2015.006098. Epub 2016 May 10.

PMID:
27165487
13.

Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial.

Sonnenblick A, de Azambuja E, Agbor-Tarh D, Bradbury I, Campbell C, Huang Y, Dueck AC, Pritchard KI, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Perez EA, Piccart M, Azim HA Jr.

J Natl Cancer Inst. 2016 Apr 20;108(8). pii: djw037. doi: 10.1093/jnci/djw037. Print 2016 Aug.

PMID:
27098150
14.

Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.

Denduluri N, Somerfield MR, Eisen A, Holloway JN, Hurria A, King TA, Lyman GH, Partridge AH, Telli ML, Trudeau ME, Wolff AC.

J Clin Oncol. 2016 Jul 10;34(20):2416-27. doi: 10.1200/JCO.2016.67.0182. Epub 2016 Apr 18.

PMID:
27091714
15.

A qualitative study of experienced nurses' voluntary turnover: learning from their perspectives.

Hayward D, Bungay V, Wolff AC, MacDonald V.

J Clin Nurs. 2016 May;25(9-10):1336-45. doi: 10.1111/jocn.13210. Epub 2016 Mar 16.

PMID:
26990238
16.

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU.

J Clin Oncol. 2016 Mar 20;34(9):945-52. doi: 10.1200/JCO.2015.63.0343. Epub 2016 Feb 1.

17.

Managing and mitigating conflict in healthcare teams: an integrative review.

Almost J, Wolff AC, Stewart-Pyne A, McCormick LG, Strachan D, D'Souza C.

J Adv Nurs. 2016 Jul;72(7):1490-505. doi: 10.1111/jan.12903. Epub 2016 Jan 29. Review.

PMID:
26822008
18.

Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907.

Lichtman SM, Cirrincione CT, Hurria A, Jatoi A, Theodoulou M, Wolff AC, Gralow J, Morganstern DE, Magrinat G, Cohen HJ, Muss HB.

J Clin Oncol. 2016 Mar 1;34(7):699-705. doi: 10.1200/JCO.2015.62.6341. Epub 2016 Jan 11.

19.

Improving an electronic system for measuring PROs in routine oncology practice.

Wu AW, White SM, Blackford AL, Wolff AC, Carducci MA, Herman JM, Snyder CF; PatientViewpoint Scientific Advisory Board..

J Cancer Surviv. 2016 Jun;10(3):573-82. doi: 10.1007/s11764-015-0503-6. Epub 2015 Dec 7.

20.

Cancer susceptibility genes and their potential implication regarding systemic therapy for early-stage breast cancer.

Karp JE, Wolff AC.

Cancer. 2016 Jan 15;122(2):178-80. doi: 10.1002/cncr.29613. Epub 2015 Dec 7. No abstract available.

Supplemental Content

Loading ...
Support Center